

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Dean Engelhardt et al. )  
Serial No.: 08/486,069 )  
Filed: June 7, 1995 )  
For: NUCLEIC ACID SEQUENCING PROCESSES )  
USING NON-RADIOACTIVE MODIFIED OR LABELED )  
NUCLEOTIDES OR NUCLEOTIDE ANALOGS, AND )  
OTHER PROCESSES FOR NUCLEIC ACID DETECTION )  
AND CHROMOSOMAL CHARACTERIZATION USING )  
SUCH NON-RADIOACTIVE DETECTABLE MODIFIED )  
OR LABELED NUCLEOTIDES OR NUCLEOTIDE )  
ANALOGS (AS PREVIOUSLY AMENDED) )

#58/W  
Group Art Unit: 1631 Plunkett  
Ex'r: Ardin H. Marschel, Ph.D. (NE)

Response to  
non-compl and  
needed first

527 Madison Avenue (9<sup>th</sup> Floor)  
New York, New York 10022  
March 12, 2001



FILED BY EXPRESS MAIL

Honorable Commissioner of Patents and Trademarks  
Washington, D.C. 20231

COMMUNICATION FOR TRANSMITTING SECOND COMPOSITE CLAIM SET  
(FOLLOWING APPLICANTS' MARCH 9, 2001  
AMENDMENT UNDER 37 C.F.R. §1.115)

Dear Sirs:

This Communication follows Applicants' March 9, 2001 Amendment  
Under 37 C.F.R. §1.115 which was in response to the January 30, 2001  
Office Action issued in connection with the above-identified application.  
Because the purpose of this Communication is to transmit a composite claim  
set, which submission is within the three month period set forth in the  
January 30, 2001 Office Action, no extension request or fee is believed due  
in connection with this Communication.

EXPRESS MAIL CERTIFICATE	
"Express Mail" Label No. <u>EL839968874US</u>	
Deposit Date	<u>March 12, 2001</u>
I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington DC 20231.	
<u>Ronald C. Fedus</u> Ronald C. Fedus Reg. No. 32,567	
MAR 12 2001 Date	

Dean L. Engelhardt, III  
Serial No.: 08/486,069  
Filed: June 7, 1995


Page 3 [Communication For Transmitting Second Composite Claim Set (Following  
Applicants' March 9, 2001 Amendment Under 37 C.F.R. §1.115 (In  
Response To The January 30, 2001 Office Action)) - March 12, 2001]

**SUMMARY AND CONCLUSIONS**

Claims 569-717, 719-869, 871-1021, 1023-1173, 1175-1294,  
1296-1407, 1409-1568, 1570-1612 and 1614-1727 continue to be  
presented for further examination in this application. No changes to the  
claims have been effected by this Communication.

No fee or fees are believed to be due in connection with this  
Communication. In the event that any other fee or fees are due, however,  
authorization is hereby given to charge the amount of any such fee(s) to  
Deposit Account No. 05-1135, or to credit any overpayment thereto.

If a telephone conversation would further the prosecution of the  
present application, Applicants' undersigned attorney request that he be  
contacted at the number provided below.

Respectfully submitted,  
  
Ronald C. Fedus  
Registration No. 32,567  
Attorney for Applicants

ENZO DIAGNOSTICS, INC.  
c/o ENZO BIOCHEM, INC.  
527 Madison Avenue, 9<sup>th</sup> Floor  
New York, New York 10022  
Telephone: (212) 583-0100  
Facsimile: (212) 583-0150

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Engelhardt et al.  
Serial No. 08/486,069 Group Art Unit: 1631  
Filed: June 7, 1995 Examiner: Ardin H. Marschel, Ph.D.  
Title: NUCLEIC ACID SEQUENCING PROCESSES USING NON-RADIOACTIVE  
MODIFIED OR LABELED NUCLEOTIDES OR NUCLEOTIDE ANALOGS, AND  
OTHER PROCESSES FOR NUCLEIC ACID DETECTION AND  
CHROMOSOMAL CHARACTERIZATION USING SUCH NON-RADIOACTIVE  
MODIFIED NUCLEOTIDES OR NUCLEOTIDE ANALOGS (As Previously Amended)

MAR 12 2001  
PATENT & TRADEMARK OFFICE  
U.S. GOVERNMENT

**FILED BY EXPRESS MAIL**

Honorable Commissioner of  
Patents and Trademarks  
Washington, D. C. 20231

Sir:

Transmitted herewith is a Communication For Transmitting Second  
Composite Claim Set (Following Applicants' March 9, 2001 Amendment Under 37  
C.F.R. §1.115) in the above-identified patent application.

The fee has been calculated as shown below:


	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
Total	1619	Minus	1619	= 0	X \$ 18	\$ 0
Indep	24	Minus	24	= 0	X \$ 80	\$ 0
( )	First Presentation of Multiple Dependent Claims				+\$270	\$ 0
	<b>TOTAL ADDITIONAL FEE</b>					<b>\$ 0</b>

( ) Charge Deposit Account No. 05-1135 in the amount of \$ \_\_\_\_\_.  
( ) A check in the amount of \$ \_\_\_\_\_ is attached.  
(X) The Commissioner is hereby authorized to charge payment of the following  
fees associated with this communication or credit any overpayment to  
Deposit Account No. 05-1135: any filing fees under 37 C.F.R. §1.16 for the  
presentation of extra claims and any patent application processing fees under  
37 C.F.R. §1.17.

Copies are being provided in triplicate.

Also enclosed: \_\_\_\_\_

Respectfully submitted,

  
Ronald C. Fedus  
Registration No. 32,567  
Attorney for Applicant(s)

ENZO DIAGNOSTICS, INC.  
c/o Enzo Biochem, Inc.  
527 Madison Avenue (9<sup>th</sup> Fl.)  
New York, New York 10022  
Tel. (212) 583-0100  
Attorney's Docket No.: Enz-5(D8)(C2)

EXPRESS MAIL CERTIFICATE	
"Express Mail" Label No. EL839968874US	
Deposit Date	March 12, 2001
I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington DC 20231.	
Ronald C. Fedus Reg. No. 32,567	MAR 12 2001 Date